3Nicolau D P, Nightingale C H, Banevicius M A, et al. Serum bactericidal activity of ceftazidime., continuous infusion versus intermittent injections[J]. Antimicrobial Agents and Chemotherapy, 1996,40(1) :61 - 64.
4Casragnola E, Ros L. Temporary interruption of ceftazidime continuous infusion without reduction of activity: a computer-assisted simulation[J].Journal of Chemotherapy, 2001,13 : 395 - 401.
5Young R J, Lipman J, Gin T, et al. Intermittent bolus dosing of ceftazidime in critically ill patients[J].Journal of Antimicrobial Chemotherapy, 1997,40(2) :269 - 273.
6Hitt C M, Klesper M E, Nigtingale C H, et al. Pharmacoeconomic impact of a once daily aminoglucoside administration[J]. Pharmacotherapy, 1997,17 : 810 - 816.
7Ambrose P G, Quintiliani R, Nigtingale C H, et al. Continuous vs intermittent infusion of cefuroxime for the treatment of community acquired pneumonia[J]. Infectious Disease and Clinical Practice, 1998,7:463 - 472.
8He F J ,Zhang X Q, Zhou J D, et al. A new MSPQC system for rapid detection of pathogens in clinical samples[J]. Journal of Microbiological Methods, 2006,66 (1):56 - 62.
9He F J, Zhou J. A new antimicrobial susceptibility testing method of Escherichia coli against ampicillin by MSPQC[J].Journal of Microbiological Methods, 2007,68(3) : 563 - 567.
